Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Attempting to right its financial course, ImmunoGen has handed over rights to several compounds to Sanofi in exchange for $30 million. The deal amends a long-running collaboration with Sanofi, which gains a license to assets including isatuximab, an antibody in Phase III studies for multiple myeloma, and SAR566658, an antibody-drug conjugate in Phase II trials for breast cancer. Last month, ImmunoGen took in another $30 million after Debiopharm bought the rights to IMGN529, an ADC in early-stage studies for B-cell cancers. Last September, ImmunoGen laid off 17% of its staff in an effort to save cash.
This article has been sent to the following recipient: